France Phillipe Archinard CEO of Transgene shares insights on the latest technologies being developed by the gene therapy specialist, explains how France’s innovation landscape is improving, and highlights the current opportunities in the market. Thanks to their versatility, oncolytic viruses can, therefore, be very potent. Our Invir.IO™ platform will be…
China William Wei Cao, chairman and CEO of Gracell, shares the fascinating journey that inspired him to establish Gracell in Shanghai to tackle the four big challenges facing the global CAR-T industry; the four novel technology platforms Gracell is working on that are already drawing significant investor and Big Pharma interest;…
France André Choulika, Chairman and CEO of Cellectis, discusses how UCART will revolutionize cell therapy as a universal gene-edited solution as opposed to the current therapies on the market which uses a patient’s own re-engineered T-cells. Choulika goes on to share how the company is positioning itself for its anticipated commercialization…
UK Keith Thompson, CEO of the Cell & Gene Therapy Catapult, one of a number of Catapult institutions in the UK designed to help commercialize innovative research, discusses strategy, funding, international collaboration and Brexit. Most likely, the UK is the best environment for putting forward trials that are properly…
See our Cookie Privacy Policy Here
